Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 4/2020

01.12.2020 | editorial

Homologous recombination deficiency: New biomarkers in innovative treatments

verfasst von: MD, MPH Christian F. Singer

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten
share
TEILEN

Excerpt

Homologous recombination (HR) is a key DNA repair mechanism that is essential for maintaining genome stability. It is characterized by its high fidelity and efficiency, and represents the pivotal repair mechanism for DNA double-strand breaks. Although known for years, its potential role as a therapeutic target has only recently been elucidated: malignant breast and ovarian tumors with mutations in the breast cancer susceptibility genes BRCA1 and BRCA2, two genes that are quintessential members of the homologous recombination repair (HRR) pathway, have been demonstrated to be particularly sensitive to poly-ADP ribose polymerase inhibitors (PARPi), such as talazoparib and olaparib. In addition, BRCA-associated HR deficiency (HRD) renders tumors particularly sensitive to platinum-based chemotherapy. …
Literatur
Metadaten
Titel
Homologous recombination deficiency: New biomarkers in innovative treatments
verfasst von
MD, MPH Christian F. Singer
Publikationsdatum
01.12.2020
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2020
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-020-00660-7